Trends of Antimicrobial Resistance and Combination Susceptibility Testing of Multidrug-Resistant Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients: a 10-Year Update-Reference-Cited by-同舟云学术

Trends of Antimicrobial Resistance and Combination Susceptibility Testing of Multidrug-Resistant Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients: a 10-Year Update

Published:2021-05-18 Issue:6 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Okoliegbe Ijeoma N.¹^ORCID,Hijazi Karolin²^ORCID,Cooper Kim¹,Ironside Corinne¹,Gould Ian M.¹

Affiliation:

1. Department of Medical Microbiology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom

2. Institute of Dentistry, University of Aberdeen, Aberdeen, United Kingdom

Abstract

Antimicrobial combination therapy is a time/resource-intensive procedure commonly employed in the treatment of cystic fibrosis (CF) pulmonary exacerbations caused by Pseudomonas aeruginosa . Ten years ago, the most promising antimicrobial combinations were proposed, but there has since been the introduction of new β-lactam plus β-lactamase inhibitor antimicrobial combinations.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02483-20

Reference28 articles.

1. The problems of antibiotic resistance in cystic fibrosis and solutions

2. In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates

3. Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data

4. Multicentre study of the in vitro activity of ceftolozane/tazobactam and other commonly used antibiotics against Pseudomonas aeruginosa isolates from patients in the UK

5. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibacterial peptide Reg4 ameliorates Pseudomonas aeruginosa -induced pulmonary inflammation and fibrosis;Microbiology Spectrum;2024-05-02

2. Pseudomonas aeruginosa heme metabolites biliverdin IXβ and IXδ are integral to lifestyle adaptations associated with chronic infection;mBio;2024-03-13

3. Effect of malate on the activity of ciprofloxacin against Pseudomonas aeruginosa in different in vivo and in vivo -like infection models;Antimicrobial Agents and Chemotherapy;2023-11-15

4. Cationic Polymers Enable Internalization of Negatively Charged Chemical Probes into Bacteria;ACS Chemical Biology;2023-09-06

5. In vitro, in vivo and clinical studies comparing the efficacy of ceftazidime-avibactam monotherapy with ceftazidime-avibactam-containing combination regimens against carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa isolates or infections: a scoping review;Frontiers in Medicine;2023-09-04